Device Trial Radar · NCT02087501
HORIZON CE Pivotal Study to Treat Abdominal Aortic Aneurysm
Last checked: Nov 20, 2026Latest source record: Dec 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Apr 2014
Primary completion
Apr 2015
Study completion May 2021
Sponsor
- Lead sponsor
- Endospan Ltd.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 14, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Clinical Investigation Design A prospective, open-label, non-randomized, interventional clinical study, sponsored by Endospan Ltd. Patients will be followed-up for five years. Investigational Device The Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System. Purpose The purpose of the study is to evaluate the safety and performance of the Horizon™ AAA Stent Graft System for the treatment of infrarenal abdominal aortic and/or aortoiliac aneurysms. The results of this study will be used as supportive data for CE Marking submission in the European Union (EU). Objectives The primary objectives of the study are to evaluate the safety and performance of the Horizon™ AAA Stent graft System. Primary End Points Safety endpoints include proportion of patients free from device related Major Adverse Events (MAEs) within 1 month of the endovascular procedure. Performance endpoints include successful delivery and deployment of the device; and absence of the following at 1 month follow-up: aneurysm growth ≥5mm, type I or III endoleaks, stent graft occlusion, conversion to open surgery, rupture and stent graft migration. Subject population Thirty (30) patients having infrarenal abdominal aortic and/or aortoiliac aneurysms, having Iliac/femoral access vessel morphology that is compatible with vascular access techniques and devices. Treatment All patients will be treated by implantation of the Horizon™ Abdominal Aortic Aneurysm Stent graft System.
Conditions
- Infrarenal Abdominal Aortic Aneurysms
- Aortoiliac Aneurysms
Interventions
Horizon™ Abdominal Aortic Aneurysm Stent Graft SystemDevice
All patient eligible to undergo stent implantation will receive the Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Endpoint: Major Adverse Events (MAEs)Time frame: 1 month post implantation
- Performance EndpointTime frame: 1 month post implant
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Nuovo Ospedale Civile S. Agostino Estense - Chirurgia vascolare
Modena, Italy
Azienda Ospedaliera Arcispedale S. Maria Nuova
Reggio Emilia, Italy
Azienda Ospedaliera Ordine Mauriziano di Torino
Torino, Italy
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.